riluzole has been researched along with Ophthalmoplegia, Progressive Supranuclear in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensimon, G | 1 |
| Ludolph, A | 1 |
| Agid, Y | 1 |
| Vidailhet, M | 1 |
| Payan, C | 1 |
| Leigh, PN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy[NCT02422485] | Phase 1 | 10 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes)[NCT00211224] | Phase 3 | 800 participants | Interventional | 2000-04-30 | Terminated | ||
| A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy[NCT02460731] | Phase 1 | 6 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies[NCT01056965] | Phase 1 | 12 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticoba[NCT02133846] | Phase 1 | 44 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for riluzole and Ophthalmoplegia, Progressive Supranuclear
| Article | Year |
|---|---|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
Topics: Aged; Disease Progression; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple System | 2009 |